AllianceBernstein
OTLK icon

AllianceBernstein’s Outlook Therapeutics OTLK Stock Holding History

AllianceBernstein’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,527
Closed -$35.7K – 3171
2023
Q4 		$35.7K Sell
4,527
-872
-16% -$7.37K ﹤0.01% 3156
2023
Q3 		$23.9K Sell
5,399
-572
-10% -$12.7K ﹤0.01% 3168
2023
Q2 		$208K Buy
5,971
+3,776
+172% +$103K ﹤0.01% 2972
2023
Q1 		$47.9K Hold
2,195
– – ﹤0.01% 3100
2022
Q4 		$47.4K Buy
2,195
+530
+32% +$11.5K ﹤0.01% 3180
2022
Q3 		$41K Buy
1,665
+250
+18% +$5.81K ﹤0.01% 3188
2022
Q2 		$29K Buy
+1,415
New +$40.7K ﹤0.01% 3190
2021
Q3 		– Sell
-850
Closed -$42K – 3328
2021
Q2 		$42K Buy
+850
New +$39.4K ﹤0.01% 3281

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

AllianceBernstein's OTLK Position: Q1 2024 in Review

AllianceBernstein sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 4,527 shares — an estimated $35.7K sold.

AllianceBernstein first reported a position in OTLK in Q2 2021 and held it in 8 quarters. The position peaked at $208K in Q2 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • AllianceBernstein reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AllianceBernstein sold 4,527 Outlook Therapeutics shares in Q1 2024, an estimated $35.7K.
  • AllianceBernstein first reported a position in Outlook Therapeutics in Q2 2021 and held it in 8 quarters.
  • AllianceBernstein's Outlook Therapeutics position peaked at $208K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on AllianceBernstein's 13F filing for Q1 2024, filed 14 May 2024.